Skip Navigation



Rheumatology Advance Access published online on June 23, 2009
Rheumatology, doi:10.1093/rheumatology/kep147
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/9/1166    most recent
kep147v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Frikha, F.
Right arrow Articles by Benveniste, O.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frikha, F.
Right arrow Articles by Benveniste, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases

Faten Frikha1, Aude Rigolet1, Anthony Behin2, Bruno Fautrel3, Serge Herson1,2 and Olivier Benveniste1,2

1Assistance Publique - Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Médecine Interne 1,2Assistance Publique - Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Centre de Référence des Pathologies Neuromusculaires Paris Est, Institut de Myologie and 3Assistance Publique - Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Rhumatologie, Paris, France

Correspondence to: Olivier Benveniste, Service de Médecine Interne 1, Groupe Hospitalier Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France. E-mail: olivier.benveniste@psl.aphp.fr

The first 10% of the full text of this article appears below.

SIR, The anti-Jo1 (histidyl tRNA synthetase) antibodies are often associated with myositis, arthritis, RP, mechanic's hand and interstitial lung disease (ILD), the latter governing the prognosis of this anti-synthetase syndrome. A 49-year-old woman presented marked muscular weakness (psoas and deltoids MRC 3/5, legs held outstretched at 45° supine: 22 s, normal >75 s) with anti-Jo1 antibodies. Creatine kinase (CK) level was 1114 U/l (N < 170 U/l). Muscle biopsy confirmed myositis. CT scan was normal. The patient was treated with prednisone 1 mg/kg/day (60 mg/day) associated with AZA (150 mg/day). Three months later, she improved (psoas . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?